SUMMARY The effect of Corwin, a new oral beta, partial agonist, on the ventricular response to atrial fibrillation was studied in digitalised patients during 24 hour ambulatory electrocardiography and during exercise on a treadmill in a double blind placebo controlled crossover trial. Corwin reduced the maximum heart rate during exercise from 162(16) beats/min to 120(9) beats/min and reduced the peak heart rate during ambulatory electrocardiography from 113(11) to 90(6) beats/min consistent with a beta adrenoreceptor antagonist action at higher levels of sympathetic nervous system activity. Minimum heart rate during ambulatory electrocardiography was increased from 62(5) to 70(5) beats/min indicating that at lower levels of sympathetic activity the drug acts as a beta agonist. The drug increased exercise tolerance significantly. Serunm digoxin concentrations were not affected by the drug.
It has been shown that digoxin may be inadequate in controlling the ventricular response to atrial fibrillation during both exercise and stress in some patients. ' 2 Corwin ((+) -1 -(4 -hydroxyphenoxy) -3 - [2 - (4 - morpholine carbonamido) ethylamino] -propan -2 -ol fumerate) is a new betal adrenoceptor partial agonist, which is currently being evaluated for the treatment of mild to moderate cardiac failure and angina. Animal experiments have shown that it attenuates the chronotropic response to sympathetic stimulation. 3 In normal volunteers4 and in a single blind placebo controlled study in 10 patients with moderately severe left ventricular dysfunction, the resting heart rate was unaffected but the chronotropic response to higher levels of exercise was attenuated by the drug (unpublished observations). Observations in normal volunteers have shown an increase in systolic blood pressure and shortening of systolic time intervals consistent with positive inotropic properties. efficacy of oral Corwin in controlling heart rate over a 24 hour period during chronic atrial fibrillation, (b) to evaluate its efficacy in controlling heart rate response during maximal exercise in patients with chronic atrial fibrillation, (c) to study its effect on exercise tolerance in patients with chronic atrial fibrillation, and (d) to study its effect on serum digoxin concentrations in patients with chronic atrial fibrillation.
Patients and methods

STUDY POPULATION
Ten patients (eight women and two men, mean age 52(8-7) years, range 39-69 years) were studied. Table   1 gives the clinical diagnosis and treatment. Three patients had symptoms in the New York Heart Association (NYHA) class I, five in class II, and two in class III. They all had documented atrial fibrillation of more than one year's duration. None took any other antiarrhythmic agent apart from digoxin. For admission to the study, the serum digoxin concentration 10 hours after the last dose had to be :0-7 ng/ ml.,'
Informed consent to participate in the study was obtained from all patients.
Effect of Corwin on heart rate in digitalised patients in attialfibrillation and at the end of each treatment phase. Exercise tolerance was measured on the Marquette TM case computer assisted system for exercise (Marquette Electronics Inc, Milwaukee, USA) using the standard Bruce protocol.6 A maximal symptom limited exercise test was performed. Modified leads VI, V5, and aVF were continuously monitored during the test. Serum digoxin concentrations were determined at each exercise test 10-12 hours after the last dose of digoxin. The double product was derived from the product of the systolic blood pressure and heart rate at the end of each stage of exercise.
All results are given as mean (standard deviation) and analysed using the paired t test. The mean hourly heart rate during placebo treatment was higher between 0800 hours and 1500 hours than during treatment with Corwin. It was lower with placebo b:tween 1600 hours and 0700 hours (Fig. 1) .
EXERCISE TESTING
Heart rate-The mean resting heart rate with digoxin and placebo was significantly higher than the mean resting heart rate with Corwin (p<0-01) ( Table  2 , Fig. 2 ). After three minutes' exercise the mean heart rate with placebo was significantly higher than that with Corwin (p<0.0005). The peak exercise heart rate was lower with Corwin than with placebo (p<0oOOO5).
Blood pressure-There was no significant difference in the resting systemic systolic blood pressure with placebo or Corwin. At three minutes' exercise and at peak exercise the mean systemic systolic blood pressure with placebo was significantly higher than that with Corwin (p<0-05 and p<0 0025 respectively). Double product-At peak exercise the mean double product with Corwin was significantly lower than that with placebo (p<0-0005).
Exercise capacity-The mean maximum exercise time with Corwin was significantly higher than that with placebo (p<0.0025) (Fig. 3) . The 
Discussion
Corwin is a new betal adrenoreceptor partial agonist.
Previous studies have shown that at rest, when the sympathetic activity is low, it increases the heart rate, whereas during exercise it attenuates the chronotropic response.3 This indicates that the beta, antagonist effect of Corwin is evident only when the sympathetic tone is high. In a single blind placebo controlled study in 10 patients with moderately severe left ventricular dysfunction exercise tolerance was improved by the drug (unpublished observations).
In this study heart rate was significantly lower during treatment with Corwin and digoxin than with placebo and digoxin between 1100 hours and 1500 hours. These were periods when the patients were likely to be more active and have a high sympathetic activity; hence Corwin showed its betal antagonist property. During the period between 1600 and 0300 hours, a period of presumed lesser activity, the hourly heart rate was higher with digoxin and Corwin than with digoxin and placebo. During this period, Corwin probably showed its betal agonist property.
Although the systemic systolic blood pressure -was Effect of Corwin on heart rate in digitalised patients in atrialfibnillation
In the previous studies showing the beta1 adrenoreceptor partial agonist activity of Corwin the subjects were in sinus rhythm. The attenuation of the exercise heart rate response in these subjects was probably mediated by the effect of Corwin on the sinus node. By contrast, in this study of patients with atrial fibrillation, the effect of Corwin on exercise heart rate response was presumably mediated by attenuation of the sympathetic enhancement of atrioventricular node conduction.
Unlike verapamil,8 whici' may also be used with digoxin to control the ventricular response to atrial fibrillation, Corwin did not affect the serum concentration of digoxin and is thus less likely to lead to digoxin toxicity.
At therapeutic serum concentrations digoxin may be inadequate for the control of ventricular response to atrial fibrillation.' 2 The addition of Corwin orally 200 mg twice daily may lead to a better control of the ventricular response throughout 24 hours. The exercise heart rate response is better controlled with this combination. The serum digoxin concentration is not altered by this addition, and hence the improvement in control is due to the effect of Corwin rather than to an increase in the serum digoxin concentration. 
